UBS Group set a €120.00 ($148.15) price target on Merck KGaA (FRA:MRK) in a research report released on Thursday, www.boersen-zeitung.de reports. The firm currently has a buy rating on the healthcare company’s stock.
Several other analysts have also weighed in on MRK. Independent Research set a €88.00 ($108.64) price objective on shares of Merck KGaA and gave the company a neutral rating in a research note on Thursday. Warburg Research set a €115.00 ($141.98) price target on shares of Merck KGaA and gave the company a buy rating in a research note on Wednesday. JPMorgan Chase & Co. restated a neutral rating on shares of Merck KGaA in a research note on Thursday. Kepler Capital Markets set a €111.00 ($137.04) price target on shares of Merck KGaA and gave the company a buy rating in a research note on Monday, March 5th. Finally, Berenberg Bank set a €111.00 ($137.04) price target on shares of Merck KGaA and gave the company a buy rating in a research note on Thursday. Twelve research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. Merck KGaA has an average rating of Hold and an average target price of €102.86 ($126.99).
Shares of Merck KGaA (FRA MRK) opened at €78.48 ($96.89) on Thursday. The firm has a market cap of $10,080.00 and a price-to-earnings ratio of 13.12. Merck KGaA has a one year low of €76.60 ($94.57) and a one year high of €115.00 ($141.98).
About Merck KGaA
MERCK Kommanditgesellschaft auf Aktien provides products in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat colorectal cancer, head and neck tumors, multiple sclerosis, infertility, growth hormone disorders, cardiovascular disorders, diabetes, and thyroid disorders; diagnostics and prescription drugs for allergen immunotherapy; and biosimilars for oncology and inflammatory disorders.
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.